Alderaan Biotechnology raise 18.5m in Series A financing
Following a 1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised 18.5m in a Series A round led by Advent France Biotechnology and Medicxi.
North Sea Therapeutics raises US$40m in Series B
NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
Merck and 4SC collaborate in immunooncology
4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat.
Novo Holdings invest US$12m in AMR companies
Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Fighting sepsis mortality
Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Antabio SAS advances cystic fibrosis programme
Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Hydrogel fights wound infection and inflammation
Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
Merry Christmas and a Happy New Year
European Biotechnology Magazine will be back with breaking news and backgrounds on 2 January.
Best wishes
British diagnostics play OBD lands contract with US pharma
The technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic biomarker discovery and development platform causing a share price gain of 15%.
Truffle’s BioMedTech fund filled with 250m
Paris-based European venture capital company Truffle Capital closed its 250m BioMedTech fund celebrating its company building approach.